Cover ImageSALE


Sickle-cell Anemia Therapeutics Market in the US 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 322845
出版日期 內容資訊 英文 51 Pages
Back to Top
美國的鐮狀細胞貧血治療市場 Sickle-cell Anemia Therapeutics Market in the US 2015-2019
出版日期: 2015年01月07日 內容資訊: 英文 51 Pages



第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 疾病概要

第6章 簡介

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 購買標準

第9章 市場成長因素

第10章 成長因素與其影響

第11章 市場課題

第12章 成長因素與課題的影響

第13章 市場趨勢

第14章 趨勢與其影響

第15章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 開發平台分析
  • 市場佔有率分析

第16章 有未來潛力的供應商

第17章 主要供應商分析

  • Bristol-Myers Squibb

第18章 相關報告

Product Code: IRTNTR5130

About Sickle-cell Anemia

Sickle-cell anemia is a disease characterized by the presence of sickle-shaped erythrocytes. While normal erythrocytes have a life span of 120 days, sickle-shaped erythrocytes die within 10 to 20 days. The bone marrow is unable to compensate for the excessive loss of erythrocytes, thereby leading to anemia. It is an inheritable disorder passed on across generations. The prevalence of the sickle-cell gene varies between different ethnic groups and geographical locations.

TechNavio's analysts forecast the Sickle-cell Anemia Therapeutics market in the US to grow at a CAGR of 17.10 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Sickle-cell Anemia Therapeutics market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated through the sales of the US FDA-approved drugs used for the treatment of sickle-cell anemia.

TechNavio's report, Sickle-cell Anemia Therapeutics Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the Sickle-cell Anemia Therapeutics market landscape in the US and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

  • Bristol-Myers Squibb
  • Future Prominent Vendors
  • Baxter
  • Bluebird Bio
  • Daiichi Sankyo
  • Eli Lilly
  • Emmaus Medical
  • GlycoMimetics
  • HemaQuest Pharmaceuticals
  • Mast Therapeutics
  • Merck Sharp & Dohme
  • Pfizer
  • Selexys Pharmaceuticals

Market Driver

  • Unmet Medical Needs
  • For a full, detailed list, view our report

Market Challenge

  • Side Effects Associated with Current Therapies
  • For a full, detailed list, view our report

Market Trend

  • Increased Focus on Adult Patients
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offering

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Disease Overview

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Buying Criteria

09. Market Growth Drivers

10. Drivers and their Impact

11. Market Challenges

12. Impact of Drivers and Challenges

13. Market Trends

14. Trends and their Impact

15. Vendor Landscape

  • 15.1. Competitive Scenario
    • 15.1.1. Key News
    • 15.1.2. Mergers and Acquisitions
  • 15.2. Pipeline Analysis
  • 15.3. Market Share Analysis 2014

16. Future Prominent Vendors

17. Key Vendor Analysis

  • 17.1. Bristol-Myers Squibb
    • 17.1.1. Key Facts
    • 17.1.2. Business Overview
    • 17.1.3. Key Product Offerings
    • 17.1.4. Revenue by Geography
    • 17.1.5. Business Strategy
    • 17.1.6. Key Information
    • 17.1.7. SWOT Analysis

18. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Product Offering for Sickle-cell Anemia Therapeutics Market in US
  • Exhibit 2: Market Research Methodology
  • Exhibit 3: Normal erythrocytes and Sickle-shaped Erythrocytes
  • Exhibit 4: Impact of Sickled Erythrocytes on Blood Flow
  • Exhibit 5: Structure of Hemoglobin
  • Exhibit 6: Genetic Basis of Sickle-cell Anemia
  • Exhibit 7: Global Distribution of Sickle-cell Gene
  • Exhibit 8: Symptoms of Sickle-cell Disease
  • Exhibit 9: Inheritance Pattern of Sickle-cell Anemia
  • Exhibit 10: Blood Sample of Sickle-cell Disease Patients Before and After Stem Cell Transplantation
  • Exhibit 11: Laboratory Tests Recommended Before Initiation of Hydroxyurea Therapy
  • Exhibit 12: Facts for Hemoglobin Disorders
  • Exhibit 13: RuSH Project Sites
  • Exhibit 14: PHRESH: Primary Focus
  • Exhibit 15: Sickle-cell Anemia Therapeutics Market in US 2014-2019 (US$ million)
  • Exhibit 16: Life Expectancy of Sickle-cell Disease Patients in US
  • Exhibit 17: Sickle-cell Disease Treatment Demonstration Program Regional Collaborative Technical Assistance: Aims of Funding
  • Exhibit 18: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
  • Exhibit 19: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
Back to Top